| LncRNA-MALAT1 | -highly expressed in cancer; Diabetic nephropathy;
-atherosclerosis; - neurodegenerative processes |
Protein turnover Scaffolding Autophagy | -HMGB1; β-catenin;
- B-MYB; - PDGF-BB - ATG7 (miR142-3p) | -Inhibition of Tumor Cell Apoptosis;
- kidney fibrosis; restored podocytes function; - Phenotypic switching of VSMCs |
[34], [77], [81], [82] |
| LincRNA-p21 | -skin cancer
-colorectal cancer -prostate cancer |
Protein turnover | p53;
HIF-1α β-catenin Jun B mRNA | cell cycle arrest; apoptosis in keratinocytes; represses translation of cancer proteins | [7], [37], [54], [83], [84] |
| LncRNA CND1/cyclin D1 | - many cancer types;
- BCL2; -breast cancer | -Protein turnover | - TLS
-cyclin D1 | - cell cycle regulator in cancer
-benefits in breast cancer therapy | [38], [39] |
| LncRNA-HOTAIR | -breast, gastric, and colorectal tumors;
- nasopharyngeal cancer | -Protein turnover;
- Scaffold function | -PRC2
- Snurportin-1; Ataxin-1 | •cell proliferation, invasion, aggression, and metastasis; inhibition of apoptosis
• prevents cellular senescence | [31], [29], [42], [45] |
| Lnc AS Uchl1 | -neurodegenerative diseases;
-cancer; -auditory cortex senescence | Protein turnover | -MDM2;
-UPS-related proteins: p53, p14; ARF, p27KIPI, ubiquitinated proteins, monoubiquitin, BE1, PSMA7 | - intensifies translation of UCHL1, which plays an important role in the UPS system | [49], [50], [51] |
| LncRNA GAS5 |
-gastric carcinoma -prostate cancer | -Protein turnover;
-Membrane trafficking | YBX1;
E2F1; P27Kip1 | -Inhibits cellular proliferation
- a growth arrest lncRNA | [52], [85] |
| Lnc RNA PANDA | -senescence. | Membrane trafficking | FAS; BIK; p53 | inhibits DNA-damage-induced apoptosis | [86] |
| Lnc ANRASSF1 | -breast, osteosarcoma, colorectal, liver, bladder, renal cell carcinoma | -Membrane trafficking;
-Scaffold function | PRC2 | Control of proliferation, metabolism, apoptosis and senescence; histone modifications | [36], [87] |
LncRNA
Gadd7 | - is expressed in response to oxidative stress | Membrane trafficking | TDP-43, modulates Cdk6 levels | controlling cell-cycle progression | [88] |
LncRNA
7SL | -widely upregulated in cancer tissues | -Autophagy
-Protein trafficking | p53;
HuR | cellular senescence | [70], [36] |
Lnc RNA DICER1 | -ovarian cancer;
- tongue squamous cell carcinoma | Autophagy | miR-675 | -A key synthesis-related factor of miRNA related to tumor cell activities;
- cellular proliferative and invasive capacities | [89] |
| LncRNA HULC | - tumor chemoresistance;
-hepatocellular carcinoma | Autophagy | -COX-2
USP22/COX-2" axis; - Sirt1 | Increase triglyceride and cholesterol levels in hepatoma cell | [64] |
| Lnc MEG3 | -colorectal cancer
- Huntington’s disease | Autophagy
Growth arrest | MDM2;
p53 | -blocks apoptosis | [20] |
| LincRNA H19 | -breast cancer;
-human tumor growth; - Gastric Carcinogenesis | Scaffold function | -E2F1, PRC2, HuR, KSRP | -suppression of RBmRNA via miR675;
-DNA methylation; cell division cycle | [102], [103], [104] |
| LncRNA PRNCR1 | -prostate cancer
-CRC | Scaffold function | - AR | - regulation of AR-dependent gene activation events- | [74], [90] |
| LncRNA PCGEM1 | -prostate cancer | Scaffold function | - AR | -tumor type-specific super-enhancer | [74], [90] |
| LncTERC | -premature neural aging in terc KO mice | Scaffold function | TRF1, TRF2 | - Promotion of telomere extension
-controlling the survival of NSCs - prevention of premature senescence and aging | [2], [30], [91] |
| Lnc TERRA | -neural aging | Scaffold function | TRF1, TRF2 | -Suppression of telomere extension
-survival of NSCs | [2], [30] |
| Lnc ANRIL | -upregulated in prostate cancer;
- myocardial infarction - hyper-cholesterolemia | -Protein turnover;
-Scaffold function | -CBX7
- let-7a/TGF-β1/Smad signaling pathway | -proliferation and migration of prostate cancer cells
- antisenescence function -histone modification | [41] |